Tenet Healthcare’s second quarter was marked by robust operational execution, with management attributing outperformance to growth in higher-acuity care, disciplined expense controls, and technology-enabled cost management programs. CEO Saum Sutaria emphasized the company’s focus on targeted service line expansion and efficiency initiatives. These efforts enabled Tenet to navigate payer mix shifts and exchange enrollment declines, with management highlighting strong commercial and Medicaid revenue contributions, as well as volume gains in key hospital and ambulatory segments.
Is now the time to buy THC? Find out in our full research report (it’s free for active Edge members).
Tenet Healthcare (THC) Q2 CY2026 Highlights:
- Revenue: $5.63 billion vs analyst estimates of $5.42 billion (6.8% year-on-year growth, 3.9% beat)
- Adjusted EPS: $6.12 vs analyst estimates of $4.26 (43.5% beat)
- The company lifted its revenue guidance for the full year to $22.2 billion at the midpoint from $21.9 billion, a 1.4% increase
- Management raised its full-year Adjusted EPS guidance to $21.00 at the midpoint, a 19.8% increase
- EBITDA guidance for the full year is $4.93 billion at the midpoint, above analyst estimates of $4.66 billion
- Operating Margin: 26.7%, up from 15.6% in the same quarter last year
- Same-Store Sales rose 2.6% year on year (0.4% in the same quarter last year)
- Market Capitalization: $22.19 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Tenet Healthcare’s Q2 Earnings Call
- Craig Hettenbach (Morgan Stanley) asked for specific examples of cost structure improvements. CEO Saum Sutaria cited “traditional productivity strategies, contract renegotiations, and technology-driven automation,” as well as process improvements in clinical operations and support functions.
- Benjamin Rossi (J.P. Morgan) questioned the drivers of revenue growth in the ambulatory segment. Sutaria explained the focus on expanding high-acuity service lines, particularly orthopedics, urology, and robotics, and noted ongoing scaling in bariatrics and cardiovascular specialties.
- Matthew Gillmor (KeyBanc Capital Markets) probed the impact of exchange revenue declines and patient mix. CFO Sun Park clarified that the majority of lost exchange volumes converted to uninsured patients and that these trends are expected to persist through the year.
- Scott Fidel (Goldman Sachs) asked about the impact of proposed HOPPS and 340B policy changes on the ambulatory segment. Sutaria responded that the company is still evaluating potential effects and will provide more details once the regulatory landscape is clearer.
- Brian Tanquilut (Jefferies) inquired whether Tenet’s volume strength indicated market share gains. Sutaria pointed to portfolio restructuring, capital investment in growth markets, and demographic trends as factors behind healthy volume and margin returns.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be closely monitoring (1) progress on Tenet’s ambulatory acquisition pipeline and integration of high-acuity service lines, (2) the pace and sustainability of margin gains from technology-enabled cost management, and (3) the company’s ability to manage payer mix shifts and exchange enrollment headwinds. Regulatory updates to reimbursement models and further clarity on Medicaid and 340B policies will also be key signposts.
Tenet Healthcare currently trades at $259.56, up from $199.02 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
